Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?

NCT ID NCT06038461

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial is testing whether a combination of three drugs—surufatinib, temozolomide, and S-1—can shrink or control advanced neuroendocrine tumors that have not been treated before. The study includes adults aged 18 to 75 with a specific type of tumor (MGMT0/1+). Researchers will measure how many patients respond to the treatment and how long the benefits last.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of surufatinib, temozolomide, and S-1
What this could lead to: If successful, this combination could offer a new first-line treatment option for people with advanced neuroendocrine tumors.
What could go wrong: This is an early-phase trial with only 40 participants, so results may not apply broadly. The drug combination may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.